HealthCare Royalty Partners
HealthCare Royalty Partners is a global healthcare investment firm focused on providing financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm`s senior investment team has participated in 50 royalty financings valued at over $2 billion over the past decade.
For more information, visit www.healthcareroyalty.com.
Valence Life Sciences
Valence Life Sciences is a leading life sciences investment firm focused on late-stage private and micro-cap public drug development companies. Valence Advantage Life Sciences Fund II’s targeted late-stage investment strategy – in conjunction with the team’s experience, insight, and disciplined approach – has produced successful results for both its investors and portfolio companies.
Valence Advantage Life Sciences Fund II was established in 2012 by Managing Directors, Eric W. Roberts and A. Rachel Leheny, Ph.D. – one of Wall Street’s premier life sciences investment banking and research teams. Eric and Rachel have worked together since 1998. The Valence Advantage investment professionals also include managing directors, Jay Cecil and Scott Morenstein. Together the team has a collective 75 years of experience and has worked on over 200 financing and M&A transactions in the life sciences industry.
Additional information can be found at: www.valencefund.com
InterWest Partners invests in some of the world’s most promising early stage IT and healthcare businesses.
For over 30 years InterWest Partners has partnered with entrepreneurs to build winning companies. With more than 200 years of operating and investing experience, InterWest has raised $2.8 billion, completed 80 IPOs, and participated in 81 upside acquisitions. InterWest is currently investing in InterWest X, a $650M fund. In 2014, InterWest made 22 investments and managed more than 100 active investments.
Additional information can be found at: www.interwest.com
Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers (KPCB) is committed to helping entrepreneurs build sustainable technology businesses. For over 30 years, KPCB has invested in hundreds of market-defining ventures, many of which have gone public or achieved success through mergers and acquisitions. The firm focuses on new technologies and new applications of technology that will drive high-impact change.
KPCB backed companies include Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Genprobe, Google, Hybritech, IDEC Pharmaceuticals, Intuit, Netscape, Ligand Pharmaceuticals, Lotus, Nuvasive, Sun Microsystems, Symantec, Verisign and Xilinx.
Additional information can be found at: www.kpcb.com